The president and Chief Financial Officer of Vaxcyte has executed a sale of company stock valued at $530,000. This transaction reflects the executive's decision to liquidate a portion of their holdings in the firm. Details regarding the specific number of shares sold and the timing of the sale have not been disclosed. The sale comes amidst ongoing developments within the company, which is focused on advancing its vaccine candidates.
Don't miss out on breaking stories and in-depth articles.
